Cargando…

The long‐term survival of esophageal cancer in elderly patients: A multi‐center, retrospective study from China

BACKGROUND: Esophageal cancer (EC) often occurs in the elderly, and approximately 40% of patients are 70 years or older. To investigate the long‐term survival of EC in elderly patients, to provide a theoretical direction for better management and predicting survival of EC based on the hospital‐based...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Runhua, He, Yutong, Sun, Xibin, Wang, Ning, Zhang, Min, Wei, Kuangrong, Li, Huizhang, Dong, Peng, Du, Lingbin, Chen, Wanqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972158/
https://www.ncbi.nlm.nih.gov/pubmed/36210795
http://dx.doi.org/10.1002/cam4.5307
_version_ 1784898263474765824
author Li, Runhua
He, Yutong
Sun, Xibin
Wang, Ning
Zhang, Min
Wei, Kuangrong
Li, Huizhang
Dong, Peng
Du, Lingbin
Chen, Wanqing
author_facet Li, Runhua
He, Yutong
Sun, Xibin
Wang, Ning
Zhang, Min
Wei, Kuangrong
Li, Huizhang
Dong, Peng
Du, Lingbin
Chen, Wanqing
author_sort Li, Runhua
collection PubMed
description BACKGROUND: Esophageal cancer (EC) often occurs in the elderly, and approximately 40% of patients are 70 years or older. To investigate the long‐term survival of EC in elderly patients, to provide a theoretical direction for better management and predicting survival of EC based on the hospital‐based multi‐center study in China. METHODS: The study was conducted in 18 hospitals including 6 provincial hospitals, 8 municipal hospitals, and 4 county hospitals. We extracted information from medical record homepage, records of admission and discharge, and pathological diagnosis reports from the medical record department of the elderly patients at 70–84 years old to obtain the 3‐year and 5‐year overall survival (OS), and main associated factors, and to analyze the current therapeutic effect of different treatment options for elderly patients. RESULTS: The 3‐year and 5‐year OS rate of the 1013 elderly patients was 44.8% and 32.8%, respectively. Their median survival was 28.00 months. The median survival of patients with squamous cell carcinoma was longer than that of other pathological type (squamous vs. other types: 31.00 vs. 20.00 months, p = 0.018). The median survival of patients with surgery only or combined therapy was longer than that of radiotherapy, chemotherapy, and no therapy (surgery only vs. combined therapy vs. radiotherapy vs. chemotherapy vs. no therapy: 56.00 vs. 33.00 vs. 26.00 vs.18.00 vs. 16.00 months, p < 0.001). The 5‐year OS rate of patients with highly differentiated cancer was higher than that of medium differentiated and poor differentiation/undifferentiated. In multivariate analysis, the older ages, pathological stage, were independent prognostic risk factors for poor EC survival. Treatment method was independent protective factors predictive of a good EC OS. CONCLUSIONS: The survival rate of the elderly EC patients was still low in China. Age, therapy method, and pathological stage were mainly associated with the survival rate of EC in elderly patients.
format Online
Article
Text
id pubmed-9972158
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99721582023-03-01 The long‐term survival of esophageal cancer in elderly patients: A multi‐center, retrospective study from China Li, Runhua He, Yutong Sun, Xibin Wang, Ning Zhang, Min Wei, Kuangrong Li, Huizhang Dong, Peng Du, Lingbin Chen, Wanqing Cancer Med RESEARCH ARTICLES BACKGROUND: Esophageal cancer (EC) often occurs in the elderly, and approximately 40% of patients are 70 years or older. To investigate the long‐term survival of EC in elderly patients, to provide a theoretical direction for better management and predicting survival of EC based on the hospital‐based multi‐center study in China. METHODS: The study was conducted in 18 hospitals including 6 provincial hospitals, 8 municipal hospitals, and 4 county hospitals. We extracted information from medical record homepage, records of admission and discharge, and pathological diagnosis reports from the medical record department of the elderly patients at 70–84 years old to obtain the 3‐year and 5‐year overall survival (OS), and main associated factors, and to analyze the current therapeutic effect of different treatment options for elderly patients. RESULTS: The 3‐year and 5‐year OS rate of the 1013 elderly patients was 44.8% and 32.8%, respectively. Their median survival was 28.00 months. The median survival of patients with squamous cell carcinoma was longer than that of other pathological type (squamous vs. other types: 31.00 vs. 20.00 months, p = 0.018). The median survival of patients with surgery only or combined therapy was longer than that of radiotherapy, chemotherapy, and no therapy (surgery only vs. combined therapy vs. radiotherapy vs. chemotherapy vs. no therapy: 56.00 vs. 33.00 vs. 26.00 vs.18.00 vs. 16.00 months, p < 0.001). The 5‐year OS rate of patients with highly differentiated cancer was higher than that of medium differentiated and poor differentiation/undifferentiated. In multivariate analysis, the older ages, pathological stage, were independent prognostic risk factors for poor EC survival. Treatment method was independent protective factors predictive of a good EC OS. CONCLUSIONS: The survival rate of the elderly EC patients was still low in China. Age, therapy method, and pathological stage were mainly associated with the survival rate of EC in elderly patients. John Wiley and Sons Inc. 2022-10-10 /pmc/articles/PMC9972158/ /pubmed/36210795 http://dx.doi.org/10.1002/cam4.5307 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Li, Runhua
He, Yutong
Sun, Xibin
Wang, Ning
Zhang, Min
Wei, Kuangrong
Li, Huizhang
Dong, Peng
Du, Lingbin
Chen, Wanqing
The long‐term survival of esophageal cancer in elderly patients: A multi‐center, retrospective study from China
title The long‐term survival of esophageal cancer in elderly patients: A multi‐center, retrospective study from China
title_full The long‐term survival of esophageal cancer in elderly patients: A multi‐center, retrospective study from China
title_fullStr The long‐term survival of esophageal cancer in elderly patients: A multi‐center, retrospective study from China
title_full_unstemmed The long‐term survival of esophageal cancer in elderly patients: A multi‐center, retrospective study from China
title_short The long‐term survival of esophageal cancer in elderly patients: A multi‐center, retrospective study from China
title_sort long‐term survival of esophageal cancer in elderly patients: a multi‐center, retrospective study from china
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972158/
https://www.ncbi.nlm.nih.gov/pubmed/36210795
http://dx.doi.org/10.1002/cam4.5307
work_keys_str_mv AT lirunhua thelongtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT heyutong thelongtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT sunxibin thelongtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT wangning thelongtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT zhangmin thelongtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT weikuangrong thelongtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT lihuizhang thelongtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT dongpeng thelongtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT dulingbin thelongtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT chenwanqing thelongtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT lirunhua longtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT heyutong longtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT sunxibin longtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT wangning longtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT zhangmin longtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT weikuangrong longtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT lihuizhang longtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT dongpeng longtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT dulingbin longtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina
AT chenwanqing longtermsurvivalofesophagealcancerinelderlypatientsamulticenterretrospectivestudyfromchina